$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmunoPrecise Antibodies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.44.
The current consensus among 1 investment analysts is to hold stock in ImmunoPrecise Antibodies.
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Read More